David Molthrop, MD
Medical Oncology · Winter Park, FLNPI 1194783027
Payments from drug & device makers
Across 154 payments — averaging $5599.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$845K
- Pfizer$14K
- AstraZeneca$2K
- Bristol Myers Squibb$441
- Gilead$235
- Genentech USA, Inc.$175
- plus $1K from 24 others
Across 2 payments — averaging $8056.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$16K
What the payments were for
- Consulting fees$11,30069%
- Travel & lodging$2,39815%
- Food & beverage$2,55616%
- Education$1161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 9 | $844,694 |
| Pfizer | 16 | $13,794 |
| AstraZeneca | 11 | $1,604 |
| Bristol Myers Squibb | 28 | $441 |
| Gilead(2 entities) | 12 | $235 |
| Genentech USA, Inc. | 11 | $175 |
| Johnson & Johnson | 8 | $155 |
| Novartis | 3 | $148 |
| E.r. Squibb & Sons, L.L.C. | 8 | $144 |
| Amgen | 4 | $91 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $91 |
| Astellas Pharma US Inc | 4 | $78 |
| Sanofi | 3 | $75 |
| EMD Serono, Inc. | 4 | $70 |
| Aurobindo Pharma USA, Inc. | 4 | $59 |
| Beone Medicines USA, Inc. | 3 | $58 |
| Beigene USA, Inc. | 4 | $57 |
| Tersera Therapeutics LLC | 2 | $52 |
| Exelixis Inc. | 3 | $52 |
| CSL Behring | 2 | $35 |
| Puma Biotechnology, Inc. | 2 | $29 |
| AbbVie | 1 | $27 |
| Incyte Corporation | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Spectrum Pharmaceuticals Inc. | 1 | $17 |
| Merck | 1 | $14 |
| Veracyte, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Seagen Inc. | 1 | $12 |
| Adaptive Biotechnologies Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$862,293 in reported general payments places this provider in the 80th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 93 | $1,340,372 |
| BrukinsaZanubrutinib | 87 | $1,109,358 |
| IbrancePalbociclib | 69 | $928,965 |
| ImbruvicaIbrutinib | 35 | $566,790 |
| JakafiRuxolitinib Phosphate | 29 | $527,903 |
| CalquenceAcalabrutinib Maleate | 28 | $411,518 |
| Lenalidomide | 22 | $321,410 |
| NinlaroIxazomib Citrate | 22 | $260,188 |
| VerzenioAbemaciclib | 12 | $181,171 |
| EliquisApixaban | 125 | $114,364 |
| XareltoRivaroxaban | 23 | $25,172 |
| Letrozole | 484 | $10,697 |
| VeozahFezolinetant | 14 | $9,030 |
| Exemestane | 56 | $8,480 |
| Anastrozole | 226 | $3,026 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $441 | $1,340,37293 claims |
| Beigene USA, Inc.Brukinsa | $57 | $1,109,35887 claims |
| PfizerIbrance, Eliquis | $13,794 | $1,043,329194 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $91 | $566,79035 claims |
| Incyte CorporationJakafi | $26 | $527,90329 claims |
| AstraZenecaCalquence | $1,604 | $411,51828 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $13 | $260,18822 claims |
| Johnson & JohnsonXarelto | $155 | $25,17223 claims |
| Astellas Pharma US IncVeozah | $78 | $9,03014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Winter Park
- Zeynep ErogluTampa$30.9M
- Manish PatelSarasota$29.7M
- Jad ChahoudTampa$21.8M
- Maen HusseinTavares$18.4M
- Patrick HwuTampa$18M
- Gail WrightHudson$13.8M
- Adil DaudTampa$13.3M
- Lowell HartFort Myers$10.1M
- Judy WangSarasota$9.8M
- Jonathan StrosbergTampa$9.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.